Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study

Abstract

BackgroundGout has an increasing global prevalence. Underutilization of urate-lowering therapy (ULT) is thought to be common, via both suboptimal dosing and poor medication adherence. The aims of this study were to determine the prevalence of self-reported gout and the key predictors of ULT use in those with gout in a representative population survey in South Australia.MethodsData were obtained from the Spring 2015 South Australian Health Omnibus Survey, a multilevel, systematic, survey in a representative population sample involving face-to-face interviews (n = 3005). This study analyzed responses from respondents aged ≥ 25 years (n = 2531) about self-reported gout, ULT use, sociodemographic factors, lifestyle factors, and comorbidities, using survey weighting. Univariate and subsequent adjusted logistic regression analyses on self-reported gout were performed. ULT use was divided into three categories (never use, prior use, and current use) and these data were analyzed using a multinomial logistic regression model.ResultsSelf-reported gout prevalence was 6.8% (95% CI 5.8, 7.9). The mean age of respondents with gout was 64 years (standard deviation 16) and 82% were male. As expected, older age, male gender, lower socioeconomic status (SES), and higher body mass index (BMI) were associated with gout, as were high alcohol consumption, current smoking, other forms of arthritis, and hypertension or hypercholesterolemia medication, after adjustment for sociodemographic variables. Two thirds of respondents with gout reported ULT use (36% current; 29% previous) with only 55% continuing treatment. Predictors of ULT use included male gender, low SES, and concomitant cholesterol-lowering therapy. Respondents with gout with a higher BMI were more likely to remain on ULT.ConclusionsDespite gout being a common, potentially disabling joint disease, only 55% of respondents with gout in this study adhered to ULT. Identification of key predictors of ULT use will provide guidance on prescribing strategy in clinical practice and on the quality of gout care in the community.Electronic supplementary materialThe online version of this article (10.1186/s13075-018-1633-9) contains supplementary material, which is available to authorized users.

Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia

“…In a recent survey of a representative sample of people in South Australia in 2018, the prevalence of gout was 6.8% . Gout is increasing in prevalence in Australia, and this is likely to be related to a combination of lifestyle factors, medication and increased awareness …”

Serum urate levels and therapy in adults treated with long‐term dialysis: a retrospective cross‐sectional study

“…It is particularly relevant to New Zealand because of the high prevalence in Māori (6%), Pacific (8%) and European (3%) people . A recent Australian study reported a similar prevalence at 6.8% (95% confidence interval (CI) 5.8–7.9) . The pathological feature of gout is excessive burden of uric acid (hyperuricaemia), defined as serum urate (SU) >0.40 mmol/L (6.8 mg/dL) .…”

Management of gout in older people

“…In the 2007–08 National Health Survey, 4.7% of working age Australians self‐reported gout . In a 2015 South Australian population survey, gout prevalence was reported to be 6.8% . In Indigenous Australians, the prevalence of gout is 3.8% overall and 7% in men according to a 2002 survey undertaken in north Queensland, but there is uncertainty about these prevalence rates .…”